abstract |
Provided herein is a therapy comprising an HDAC inhibitor (HDACi), and/or a PD-L1 and/or a PD-1 inhibitor, and/or a CTLA-4 inhibitor. The combination therapy provided herein can be a kit or the composition or a pharmaceutical composition. Also, provided herein is a method of treating cancer using the combination therapy. |